Uncategorized

Stephen Majors from the Alliance for Regenerative Medicine, which hosts the conference, spoke with BioSpace about what the more than 2,000 attendees can expect to learn next week in Phoenix about the pressing issues confronting the industry.

It’s the first time this type of model has been used to bring a Humira biosimilar to market, according to the insurer — and it yields a much lower cost than both the brand-name version of the drug and its biologic copycats.

Philips is asking customers to immediately install a software update to address several new and previously reported safety issues, the FDA said. 

Mission Hospital’s emergency department is at double capacity as supply shortages create processing delays, nurses told Healthcare Dive.

After making nearly $550 million worth of acquisitions in the past few years, the medical device contract manufacturer will use proceeds from the sale to pay down debt.

The health system has been hit with a combined $895 million in damages this year related to alleged child abuse at some of its behavioral health subsidiaries.

The e-prescribing giants’ other investors — CVS Health, Cigna-owned pharmacy benefit manager Express Scripts and two pharmacist trade groups — will retain a minority interest.

To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through thick and thin.

Big Pharma companies Bayer and Johnson & Johnson are downsizing their New Jersey workforces while Pfizer cuts jobs in Ireland. Many of the layoffs are effective by the end of the year.

ImmunityBio will lay off 15 employees in California, mostly in El Segundo, effective Nov. 25. The company is also letting go 16 employees later this month.